We conducted a clinical trial of neoadjuvant chemotherapy (NCT) versus neoadjuvant endocrine therapy (NET) in premenopausal patients with hormone-responsive, HER2-, LN+ breast cancer. Here, ERBB2 is linked to breast cancer.